公开(公告)号：US10005847B2

公开(公告)日：2018-06-26

申请号：US14723181

申请日：2015-05-27

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu

IPC: C07K16/32 ,  C07K16/40 ,  A61K31/517 ,  A61K39/395 ,  C07K16/28 ,  C12P21/00

CPC classification number: C07K16/40 ,  A61K31/517 ,  A61K39/3955 ,  C07K16/283 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/92 ,  C12P21/005 ,  C12Y302/01 ,  C12Y302/01051

Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：US09982041B2

公开(公告)日：2018-05-29

申请号：US14599174

申请日：2015-01-16

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Tsui-Ling Hsu ,  Yi-Wei Lou ,  Chih-Wei Lin ,  Shih-Chi Yeh ,  Chung-Yi Wu ,  Han-Chung Wu

IPC: C07K16/18 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57492 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：US20150273034A1

公开(公告)日：2015-10-01

申请号：US14675838

申请日：2015-04-01

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Alice L. Yu ,  John Yu

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K2039/55511 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/627 ,  C12N15/1137 ,  C12N2310/14

Abstract: An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker.

Abstract translation: 含有载体蛋白的聚糖缀合物和包含Globo H，其免疫原性片段或阶段特异性胚胎抗原-4（SSEA-4）的聚糖的免疫原性组合物，其中所述聚糖通过接头与载体蛋白缀合 。

公开(公告)号：US11332523B2

公开(公告)日：2022-05-17

申请号：US14722775

申请日：2015-05-27

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu

IPC: C07K16/24 ,  A61K39/395 ,  A61K45/06 ,  C12P21/00 ,  A61K39/00

Abstract: The present disclosure relates to a novel class of anti-TNFα monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNFα IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNFα monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：US10274488B2

公开(公告)日：2019-04-30

申请号：US14182290

申请日：2014-02-18

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Susan Y. Tseng

IPC: C40B50/00 ,  C40B50/12 ,  G01N33/553 ,  C40B40/12 ,  C40B50/14 ,  G01N33/58 ,  C40B60/00 ,  H01J49/40

Abstract: Aluminum coated glass slides provide a novel glycan array platform. Specifically, aluminum coated glass slides increase sensitivity of fluorescent based assay methods. Additionally, aluminum coated glass slides allows for mass spectroscopic analysis of carbohydrates and provide a platform for examining activity of cellulases. The unique properties of ACG slides include: 1) the metal oxide layer on the surface can be activated for grafting organic compounds such as modified oligosaccharides; 2) the surface remains electrically conductive, and the grafted oligosaccharides can be simultaneously characterized by mass spectrometry and carbohydrate-binding assay; and 3) the slides are more sensitive than transparent glass slides in binding analysis.

公开(公告)号：US10155823B2

公开(公告)日：2018-12-18

申请号：US15505763

申请日：2015-08-21

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Hsin-Yu Lee

IPC: C07H3/06 ,  A61K39/00 ,  A61K47/36 ,  A61K47/64 ,  C07K14/33 ,  C07K14/34 ,  C08B37/00

Abstract: This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.

公开(公告)号：US20180298361A1

公开(公告)日：2018-10-18

申请号：US16011622

申请日：2018-06-18

Applicant: CHO Pharma Inc. ,  Academia Sinica

Inventor： Nan-Horng Lin ,  Lin-Ya Huang ,  Sachin S. Shivatare ,  Li-Tzu Chen ,  Chi-Huey Wong ,  Chung-Yi Wu ,  Ting Cheng

IPC: C12N9/42 ,  C12P21/00 ,  C07K16/28

CPC classification number: C12N9/2434 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2319/21 ,  C12P21/005 ,  C12Y302/01096

Abstract: A mutant of Endos2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：US10000747B2

公开(公告)日：2018-06-19

申请号：US15684897

申请日：2017-08-23

Applicant: CHO Pharma Inc. ,  Academia Sinica

Inventor： Nan-Horng Lin ,  Lin-Ya Huang ,  Sachin S Shivatare ,  Li-Tzu Chen ,  Chi-Huey Wong ,  Chung-Yi Wu ,  Ting Cheng

IPC: C12N9/24 ,  C12P21/00 ,  C07K16/28 ,  C12N9/42

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：US20180057804A1

公开(公告)日：2018-03-01

申请号：US15684897

申请日：2017-08-23

Applicant: CHO Pharma Inc. ,  Academia Sinica

Inventor： Nan-Horng Lin ,  Lin-Ya Huang ,  Sachin S Shivatare ,  Li-Tzu Chen ,  Chi-Huey Wong ,  Chung-Yi Wu ,  Ting Cheng

IPC: C12N9/42 ,  C12P21/00 ,  C07K16/28

CPC classification number: C12N9/2434 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2319/21 ,  C12P21/005 ,  C12Y302/01096

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：US20160213763A1

公开(公告)日：2016-07-28

申请号：US14832993

申请日：2015-08-21

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu

IPC: A61K39/00 ,  C07H7/02 ,  C07H15/04 ,  C07K16/30

CPC classification number: A61K39/0011 ,  A61K31/7028 ,  A61K31/715 ,  A61K2039/55511 ,  A61K2039/6037 ,  A61K2039/627 ,  C07H5/02 ,  C07H5/04 ,  C07H5/06 ,  C07H15/04 ,  C07H15/26 ,  C07K16/3076 ,  C07K16/44 ,  C08B37/006

Abstract: The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.

Abstract translation: 本公开涉及针对SSEA3 / SSEA4 / GloboH相关表位（天然和修饰）的疫苗，抗体和/或免疫原性缀合物组合物，其引发可用于调节globo系列鞘糖脂合成的抗体和/或结合片段生产。 本公开涉及可以调节globo系列鞘糖脂合成的方法和组合物。 特别地，本公开涉及可以调节生物合成途径中的globo系列鞘糖脂SSEA3 / SSEA4 / GloboH的合成的糖酵母抑制剂化合物及其组合物和使用方法; 特别是糖酵解抑制剂靶向α-4GalT; β-4GalNAcT-I; 或β-3GalT-V酶在globo系列合成途径中。 此外，本公开还涉及使用本文所述的组合物治疗或检测过度增殖性疾病和/或病症的方法。